Grants per year
Personal profile
Research Interests
I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .
Training Experience
1982 | Internship, University of Chicago Hospitals |
1985 | Residency, University of Chicago Hospitals |
1986 | Residency, University of Wisconsin Hospital & Clinics |
1989 | Fellowship, University of Wisconsin Hospital & Clinics |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Albert Einstein College
… → 1981
Research interests keywords
- Genomic Medicine/Personalized Medicine
- Immunology
- Kidney Cancer / Urinary Tract Cancer
- Skin Cancer
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
Wu, J. D., Sosman, J. A., Yang, G. & Mi, X.
8/1/23 → 7/31/28
Project: Research project
-
Sustaining metabolic fitness of antitumor CD8+ T Cells
Melanoma Research Alliance Foundation
6/1/23 → 5/31/26
Project: Research project
-
SPORE in Prostate Cancer
Abdulkadir, S. A., Abdulkadir, S. A., Hussain, M., Hussain, M., Catalona, W. J., Catalona, W. J., Chakravarti, D., Chakravarti, D., Kim, K. A., Kim, K. A., Morgans, A. K., Morgans, A. K., Murphy, A. B., Murphy, A. B., Schiltz, G. E., Schiltz, G. E., Wei, J., Wei, J., Yang, R., Yu, J., Yu, J., Kocherginsky, M., Kocherginsky, M., Leikin, R. G., Leikin, R. G., Sosman, J. A., Sosman, J. A., Wu, J. D., Wu, J. D., Yang, X. J., Yang, X. J., Yang, R., Zhao, C. & Zhao, C.
9/1/21 → 7/31/26
Project: Research project
-
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., Lingua, A., Lattouf, J. B., Albigès, L., George, S., Shuch, B., Sosman, J., Staehler, M., Vázquez Estévez, S., Simsek, B., Spiridigliozzi, J., & 2 others , Mar 11 2023, In: The Lancet. 401, 10379, p. 821-832 12 p.Research output: Contribution to journal › Article › peer-review
19 Scopus citations -
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF -Mutant Melanoma: The DREAMseq Trial - ECOG-ACRIN EA6134
Atkins, M. B., Lee, S. J., Chmielowski, B., Tarhini, A. A., Cohen, G. I., Truong, T. G., Moon, H. H., Davar, D., O'Rourke, M., Stephenson, J. J., Curti, B. D., Urba, W. J., Brell, J. M., Funchain, P., Kendra, K. L., Ikeguchi, A. P., Jaslowski, A., Bane, C. L., Taylor, M. A., Bajaj, M., & 16 others , Jan 10 2023, In: Journal of Clinical Oncology. 41, 2, p. 186-197 12 p.Research output: Contribution to journal › Article › peer-review
Open Access64 Scopus citations -
Endocrine side effects of immune checkpoint inhibitors
Cardona, Z., Sosman, J. A., Chandra, S. & Huang, W., 2023, In: Frontiers in Endocrinology. 14, 1157805.Research output: Contribution to journal › Review article › peer-review
Open Access -
Melanoma: Does Sequencing Really Matter?
Chandra, S., Choi, J. S. & Sosman, J. A., Jan 10 2023, In: Journal of Clinical Oncology. 41, 2, p. 167-169 3 p.Research output: Contribution to journal › Editorial › peer-review
4 Scopus citations -
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T. G., Eisenstein, J. L., Chandra, S., Sosman, J. A., Kendra, K. L., Wu, R. C., Devoe, C. E., Deutsch, G. B., Hegde, A., Khalil, M., Mangla, A., & 33 others , 2023, In: New England Journal of Medicine. 388, 9, p. 813-823 11 p.Research output: Contribution to journal › Article › peer-review
78 Scopus citations
Datasets
-
Additional file of Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. A. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12872204, https://springernature.figshare.com/articles/dataset/Additional_file_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/12872204
Dataset
-
Additional file 1 of Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. A. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12456779, https://springernature.figshare.com/articles/Additional_file_1_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/12456779
Dataset
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. A. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5014769.v2, https://springernature.figshare.com/collections/Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/5014769/2
Dataset